Search
Protara Therapeutics Inc
TARAAdd to Watchlist
4.060USD
+0.020+0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
223.53MMarket Cap
LossP/E TTM
More Details of Protara Therapeutics Inc Company
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Protara Therapeutics Inc Info
Ticker SymbolTARA
Company nameProtara Therapeutics Inc
IPO dateOct 22, 2014
CEOShefferman (Jesse)
Number of employees28
Security typeOrdinary Share
Fiscal year-endOct 22
Address345 Park Avenue South
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10010
Phone16468440337
Websitehttps://protaratx.com/
Ticker SymbolTARA
IPO dateOct 22, 2014
CEOShefferman (Jesse)
Company Executives of Protara Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jesse Shefferman
Mr. Jesse Shefferman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
841.83K
-3.56%
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Mr. William (Bill) Conkling
Mr. William (Bill) Conkling
Chief Commercial Officer
Chief Commercial Officer
69.99K
-8.58%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
42.72K
+13.84%
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
40.83K
-76.58%
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Independent Director
Independent Director
33.00K
--
Mr. Gregory P. Sargen
Mr. Gregory P. Sargen
Independent Director
Independent Director
31.00K
--
Dr. Michael Edward (Mike) Solomon, Ph.D.
Dr. Michael Edward (Mike) Solomon, Ph.D.
Independent Director
Independent Director
26.50K
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Chief Financial Officer
Chief Financial Officer
25.95K
+83.53%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jesse Shefferman
Mr. Jesse Shefferman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
841.83K
-3.56%
Mr. Luke M. Beshar, CPA
Mr. Luke M. Beshar, CPA
Independent Chairman of the Board
Independent Chairman of the Board
198.00K
--
Mr. William (Bill) Conkling
Mr. William (Bill) Conkling
Chief Commercial Officer
Chief Commercial Officer
69.99K
-8.58%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
51.00K
--
Ms. Hannah Fry
Ms. Hannah Fry
Controller
Controller
42.72K
+13.84%
Dr. Jacqueline Zummo, Ph.D.
Dr. Jacqueline Zummo, Ph.D.
Chief Scientific Operations Officer
Chief Scientific Operations Officer
40.83K
-76.58%
FAQs
Who are the top five shareholders of Protara Therapeutics Inc?
The top five shareholders of Protara Therapeutics Inc are: Mr. Jesse Shefferman
How many institutions hold shares of Protara Therapeutics Inc (TARA)?
As of 2026Q1, 185 institutions hold shares of Protara Therapeutics Inc, with a combined market value of approximately 46.80M, accounting for 85.08% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 12603587.00.